The capacity of neural stem cells (NSC) to migrate towards areas of tissue damage within the brain underscores the potential use of these cells as agents for cell replacement and/or drug delivery in the brain. Malignant gliomas consist of infiltrating tumor cells, which are largely refractory to currently employed therapies, resulting in inevitable tumor recurrence. We have demonstrated the efficacy of using primary fetal murine NSC as delivery vehicles for cytotoxic or immunostimulatory agents to treat infiltrating glioma and have demonstrated a mechanism of glioma tropism. We also described a rapid culture process whereby multipotent neural precursors, phenotypically and morphologically distinct from bone marrow stromal cells can be generated from unfractionated adult bone marrow. These bone marrow derived neural progenitors (BM-NSC) are morphologically and phenotypically indistinguishable from fetal NSC and could differentiate into neurons, astrocytes, and oligodendroglia. BM-NSC demonstrated tumor tropic behavior in vivo and when inoculated into the hippocampus, engrafted and assumed neuronal phenotype. These findings indicate that adult bone marrow may serve as a viable source of neural progenitor cells to treat glioma and neurodegeneration. We now aim to test the hypotheses that: 1) Bone marrow derived NSC (BM-NSC) migration toward glioma is dependent on CXCR4 expression on the plasma membrane of BM-NSC. 2) BM-NSC differentiation into A2B5+, GFAP+ astrocytic precursors will promote migration toward glioma, while terminal differentiation into neurons will promote engraftment after intracranial transplantation. 3) Overexpression of Shh or Gli-1 will promote BM-NSC proliferation, while Nurr1 will promote neuronal fate and Delta-like ligand 1 will promote astrocytic fate. 4) Promoting BM-NSC proliferation and astrocytic fate will (i) lead to increased migration to glioma and (ii) increase tumor control and prolong survival in an experimental rodent glioma model.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS048959-04
Application #
7215672
Study Section
Special Emphasis Panel (ZRG1-CNBT (01))
Program Officer
Fountain, Jane W
Project Start
2004-07-01
Project End
2009-03-31
Budget Start
2007-04-01
Budget End
2009-03-31
Support Year
4
Fiscal Year
2007
Total Cost
$307,850
Indirect Cost
Name
Cedars-Sinai Medical Center
Department
Type
DUNS #
075307785
City
Los Angeles
State
CA
Country
United States
Zip Code
90048
Edwards, Lincoln A; Li, Aiguo; Berel, Dror et al. (2017) ZEB1 regulates glioma stemness through LIF repression. Sci Rep 7:69
Thomas, Tom M; Yu, John S (2017) Metabolic regulation of glioma stem-like cells in the tumor micro-environment. Cancer Lett 408:174-181
Xu, Qijin; Yuan, Xiangpeng; Yu, John S (2012) Glioma stem cell research for the development of immunotherapy. Adv Exp Med Biol 746:216-25
Milanesi, Anna; Lee, Jang-Won; Xu, Qijin et al. (2011) Differentiation of nestin-positive cells derived from bone marrow into pancreatic endocrine and ductal cells in vitro. J Endocrinol 209:193-201
Irvin, Dwain K; Jouanneau, Emmanuel; Duvall, Gretchen et al. (2010) T cells enhance stem-like properties and conditional malignancy in gliomas. PLoS One 5:e10974
Ji, Jianfei; Black, Keith L; Yu, John S (2010) Glioma stem cell research for the development of immunotherapy. Neurosurg Clin N Am 21:159-66
Xu, Qijin; Yuan, Xiangpeng; Xu, Minlin et al. (2009) Chemokine CXC receptor 4--mediated glioma tumor tracking by bone marrow--derived neural progenitor/stem cells. Mol Cancer Ther 8:2746-53
Xu, Q; Yuan, X; Tunici, P et al. (2009) Isolation of tumour stem-like cells from benign tumours. Br J Cancer 101:303-11
Xu, Qijin; Liu, Gentao; Yuan, Xiangpeng et al. (2009) Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells 27:1734-40
Xu, Qijin; Yuan, Xiangpeng; Liu, Gentao et al. (2008) Hedgehog signaling regulates brain tumor-initiating cell proliferation and portends shorter survival for patients with PTEN-coexpressing glioblastomas. Stem Cells 26:3018-26

Showing the most recent 10 out of 16 publications